# Genetic Origins of Adverse Outcomes in African Americans with Lymphoma

> **NIH NIH R01** · DUKE UNIVERSITY · 2024 · $461,406

## Abstract

ABSTRACT
Diffuse large B cell lymphoma (DLBCL) is the most common form of blood cancer and is characterized by a
striking degree of genetic heterogeneity. It has been known for some time that African American patients have
poorer outcomes than Caucasian patients. After correcting for potential differences in socioeconomics and
access to care, our data indicate that the poorer outcomes in African Americans arise primarily from distinct
genetics of their tumors. The underlying genetic causes of these poorer outcomes have not been studied
systematically. Here, we propose to investigate tumor and germline genetics of African Americans to
comprehensively understand the genetic basis of their poorer outcomes. Preliminary genomic analysis of
African American DLBCL patients has revealed more frequent mutations in histone methyltransferase genes
and other genes. In this proposal, we seek to comprehensively define the genetic origins of poor outcomes in
African Americans with DLBCL and perform functional characterization of selected genomic alterations.

## Key facts

- **NIH application ID:** 10829847
- **Project number:** 5R01CA271589-02
- **Recipient organization:** DUKE UNIVERSITY
- **Principal Investigator:** Sandeep Dave
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $461,406
- **Award type:** 5
- **Project period:** 2023-04-18 → 2028-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10829847

## Citation

> US National Institutes of Health, RePORTER application 10829847, Genetic Origins of Adverse Outcomes in African Americans with Lymphoma (5R01CA271589-02). Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/grant/nih/10829847. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*